THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Patent applications |
Patent application number | Title | Published |
20160097136 | NanoTin Catalysts for Electrochemical Reduction of Carbon Dioxide to Formate - High surface area tin oxide nanoparticles prepared by a facile hydrothermal method followed by electroreduction to tin act as electrocatalysts toward CO | 04-07-2016 |
20160024463 | BIOMATRIX SCAFFOLDS FOR INDUSTRIAL SCALE DISPERSAL - The present invention provides biomatrix scaffolds for industrial scale dispersal. | 01-28-2016 |
20150294796 | ASSEMBLIES AND METHODS OF STABILIZATION - Some embodiments of the present invention provide an assembly for harvesting light comprising a first molecule joined to a metal oxide surface through a surface linking group and a second molecule joined to the metal oxide surface. Such assemblies can harvest light to do useful chemistry, such as in a dye-sensitized photoelectrochemical cell, or a molecular catalyst-solar cell system. In other embodiments, the harvested light can be converted into electricity, such as in a dye-sensitized solar cell. Other embodiments of the present invention provide methods for stabilizing a chromophore or a catalyst on a surface. These methods are applicable, for example, to dye-sensitized photoelectrochemical cells where the surface-bound chromophores are known to be unstable under aqueous conditions. | 10-15-2015 |
20150282774 | STATIONARY GANTRY COMPUTED TOMOGRAPHY SYSTEMS AND METHODS WITH DISTRIBUTED X-RAY SOURCE ARRAYS - Systems and methods for x-ray imaging are disclosed, particularly non-rotating, stationary gantry and mobile x-ray computed tomography systems and methods for imaging a subject, and particularly for imaging the head, spine, and neck of a subject. Compared to rotating-gantry computed tomography scanners, non-rotating stationary gantry x-ray computed tomography scanners are more mobile and transportable. Non-rotating stationary gantry x-ray computed tomography scanners can thus be used in mobile transport units and in-field applications. | 10-08-2015 |
20150252355 | METHODS AND SYSTEMS FOR USING ENCAPSULATED MICROBUBBLES TO PROCESS BIOLOGICAL SAMPLES - Methods and systems for using encapsulated microbubbles to process biological samples are disclosed. According to one aspect, a method for using encapsulated microbubbles to process a biological sample includes creating a mixture comprising encapsulated microbubbles mixed with a biological sample and adding activation energy to the mixture to cause at least some of the microbubbles to oscillate or burst and thereby process the sample, including effecting cell lysis, shearing DNA, and/or performing tissue dispersion. | 09-10-2015 |
20150210972 | DISSOLUTION GUIDED WETTING OF STRUCTURED SURFACES - A microfabricated device having at least one gas-entrapping feature formed therein in a configuration that entraps air bubbles upon wetting the feature with a solvent or solution is described. The device includes a sacrificial residue in contact with the gas-entrapping feature, the dissolution of which guides the wetting of the gas-entrapping feature. | 07-30-2015 |
20150173406 | HYPOALLERGENIC FOOD-GRADE PROTEIN MATRICES AND USES THEREOF - This invention relates generally to the discovery of improved food-grade protein matrices with reduced allergeiiicity and uses thereof including immunotherapy. | 06-25-2015 |
20150147758 | DOT1 Histone Methyltransferases as a Target for Identifying Therapeutic Agents for Leukemia - The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject. | 05-28-2015 |
20150138069 | METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR UNIFIED SCENE ACQUISITION AND POSE TRACKING IN A WEARABLE DISPLAY - Methods, systems, and computer readable media for unified scene acquisition and pose tracking in a wearable display are disclosed. According to one aspect, a system for unified scene acquisition and pose tracking in a wearable display includes a wearable frame configured to be worn by a user. Mounted on the frame are: at least one sensor for acquiring scene information for a real scene proximate to the user, the scene information including images and depth information; a pose tracker for estimating the user's head pose based on the acquired scene information; a rendering unit for generating a virtual reality (VR) image based on the acquired scene information and estimated head pose; and at least one display for displaying to the user a combination of the generated VR image and the scene proximate to the user. | 05-21-2015 |
20150133372 | METHODS AND COMPOSITIONS FOR THE INDUCTION OF HYPOTHERMIA - Provided herein are methods for the induction of hypothermia and the treatment of clinical insults in a subject through the administration of a regulated hypothermic multidrug combination. The compositions or multidrug combinations of the invention comprise a regulated hypothermic compound or a dopamine receptor agonist; a vasoactive compound; and an antiarrhythmic compound or a serotonin 5-HT | 05-14-2015 |
20150110753 | BIOMATRIX SCAFFOLDS - The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same. | 04-23-2015 |
20150075621 | Molecular Assemblies and Multilayer Films for Photocurrent and Catalysis - Some embodiments of the present invention provide an assembly for harvesting light, comprising a first molecule joined to a second molecule through mutual coordination to an ion, and the first molecule is linked to a metal oxide surface having a high surface area. Such assemblies can form multilayer films, in other embodiments. The assemblies and multilayer films can harvest light to do useful chemistry, such as in a dye-sensitized photoelectrochemical cell, or can convert the harvested light into electricity, such as in a dye-sensitized solar cell. | 03-19-2015 |
20150073143 | Ruthenium or Osmium Complexes and Their Uses as Catalysts for Water Oxidation - The present invention provides ruthenium or osmium complexes and their uses as a catalyst for catalytic water oxidation. Another aspect of the invention provides an electrode and photo-electrochemical cells for electrolysis of water molecules. | 03-12-2015 |
20150072852 | Solar Water Splitting in a Molecular Photoelectrochemical Cell - A Dye Sensitized Photoelectrosynthesis Cell (DSPEC) splits water with visible light using a derivatized, core/shell nanostructured photoanode with the core having a high surface area conductive metal oxide film—such as nanoITO (indium tin oxide) or nanoATO (antimony tin oxide)—coated with a thin outer shell of, for example, TiO | 03-12-2015 |
20150051205 | SELECTIVE BETA-GLUCURONIDASE INHIBITORS AS A TREATMENT FOR SIDE EFFECTS OF CAMPTOTHECIN ANTINEOPLASTIC AGENTS - Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial β-glucuronidase and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplasatic agents or glucuronidase-substrate agents or compounds. | 02-19-2015 |
20150017665 | Peptides and Methods for Detecting MPO-ANCA - The present invention relates to disorder-specific epitopes recognized by myeloperoxidase-anti-neutrophil cytoplasmic autoantibodies and the use of polypeptides comprising the epitopes in methods of diagnosing and monitoring autoimmune disorders associated with the autoantibodies. | 01-15-2015 |
20140335496 | HUMAN CONDUCTING AIRWAY MODEL COMPRISING MULTIPLE FLUIDIC PATHWAYS - A multicellular fluidic enhanced airway model system of the conducting airways as a tool for the evaluation of biological threats and medical countermeasures is provided. The airway model system can include a first chamber having an inlet and an outlet and containing epithelial cells; a second chamber having an inlet and an outlet and containing an extracellular matrix, wherein the second chamber is separated from the first chamber by a porous membrane; and a third chamber having an inlet and an outlet, wherein the third chamber is separated from the second chamber by a porous membrane, and wherein the airway tissue model system is configured to provide a separate fluidic pathway through each of said first, second, and third chambers. A method of analyzing tissue response to an agent via an airway tissue model system is also provided. | 11-13-2014 |
20140311916 | High Surface Area Reticulated Vitreous Carbon-Nanoparticle Metal Oxide Electrodes - The present invention provides, in some embodiments, hybrid materials having reticulated vitreous carbon (RVC) and nanoparticles of a conductive, transparent metal oxide such as tin-doped indium oxide (ITO). The material can further include one or more transition metal catalysts, such as {Ru(Mebimpy)[ | 10-23-2014 |
20140308728 | NON-COVALENT BIOMOLECULE IMMOBILIZATION ON TITANIA NANOMATERIALS - A biomolecule immobilization substrate comprising a titania nanotube is provided. Stable undercoordinated titanium sites on the surface of titanium dioxide nanotubes provide for the binding of biomolecules in multiple layers and aggregates. Corresponding methods of immobilizing and storing biomolecules are provided. Enzymatic or other biological activities of titania nanotube bound biomolecules can be preserved or enhanced. | 10-16-2014 |
20140308364 | GELATINOUS HYDROXYAPATITE-NANOCOMPOSITES - A novel nanocomposite including hydroxyapatite-gelatin bioceramic material and dopamine, wherein the dopamine undergoes an oxidative self-polymerization reaction to form the novel nanocomposite. The nanocomposite displays superior mechanical strength, elasticity, biocompatibility and forming capabilities and is targeted for bone repairs and template-assisted tissue engineering applications. In addition, improved aminosilica-based hydroxyapatite-gelatin bioceramic bioceramics are disclosed. | 10-16-2014 |
20140302005 | CHIMERIC FACTOR VII MOLECULES - The present invention relates to chimeric Factor VII polypeptides and methods of using the same. | 10-09-2014 |
20140294848 | Novel Targets for Regulation of Angiogenesis - The present invention relates to the identification of polynucleotides and polypeptides having increased expression in tumor blood vessels. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of angiogenesis and the diagnosis and treatment of angiogenesis-related diseases such as cancer. | 10-02-2014 |
20140271712 | METHODS AND COMPOSITIONS FOR NOROVIRUS BLOCKADE EPITOPES - The present invention provides methods and compositions comprising a chimeric norovirus capsid protein comprising a norovirus VP1 major capsid protein backbone comprising a norovirus epitope selected from the group consisting of: a) Epitope A; b) Epitope B; c) Epitope C; d) Epitope D; e) Epitope E; f) Epitope F; and g) any combination of (a) through (f) above, wherein the norovirus epitope is from a norovirus strain that is different from the norovirus VP1 major capsid protein backbone. | 09-18-2014 |
20140271551 | Synthetic Adeno-Associated Virus Inverted Terminal Repeats - This invention relates to synthetic adeno-associated virus (AAV) inverted terminal repeats (ITRs) that exhibit altered activities compared to a naturally occurring AAV ITR and methods of using the same for delivery of nucleic acids to a cell or a subject. The synthetic ITRs provide a larger packaging capacity and the ability to manipulate activities such as transduction efficiency, cellular response to transduction, and transcription. | 09-18-2014 |
20140263999 | MICROSCALE MASS SPECTROMETRY SYSTEMS, DEVICES AND RELATED METHODS - Mass spectrometry systems or assemblies therefore include an ionizer that includes at least one planar conductor, a mass analyzer with a planar electrode assembly, and a detector comprising at least one planar conductor. The ionizer, the mass analyzer and the detector are attached together in a compact stack assembly. The stack assembly has a perimeter that bounds an area that is between about 0.01 mm | 09-18-2014 |
20140247069 | SYSTEMS, PIPELINE STAGES, AND COMPUTER READABLE MEDIA FOR ADVANCED ASYNCHRONOUS PIPELINE CIRCUITS - Systems, pipeline stages, and computer readable media for advanced asynchronous pipeline circuits are disclosed. According to one aspect, the subject matter described herein includes a configurable system for constructing asynchronous application specific integrated data pipeline circuits. The system includes multiple modular circuit stages that are connectable with each other using transitional signaling and with other circuit elements to form multi-stage asynchronous application-specific integrated data pipeline circuits for asynchronously passing data through a series of stages based on a behavior implemented by each stage. The modular circuit stages each include sets of logic gates connected to each other for implementing the behaviors, the behaviors including at least one of conditional split, conditional select, conditional join, merge without arbitration, and stage arbitration. | 09-04-2014 |
20140243315 | PYRROLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER - The ectopic expression of Mer receptor tyrosine kinase (Mer) has been identified as a tumor cell survival gene product in Acute Lymphoblastic Leukemia (ALL) cells and a potential cause of ALL chemoresistance. Hence, we investigated whether the development of small molecule Mer inhibitors was possible. A first aspect of the present invention is a compound (sometimes referred to as an “active compound” herein) of Formula I, IA, or IB. | 08-28-2014 |
20140238856 | NANOFLUIDIC DEVICES WITH INTEGRATED COMPONENTS FOR THE CONTROLLED CAPTURE, TRAPPING, AND TRANSPORT OF MACROMOLECULES AND RELATED METHODS OF ANALYSIS - Devices for controlling the capture, trapping, and transport of macromolecules include at least one fluidic transport nanochannel that intersects and is in fluid communication with at least one transverse nanochannel with (shallow) regions and/or with integrated transverse electrodes that enable fine control of molecule transport dynamics and facilitates analyses of interest, e.g., molecular identification, length determination, localized (probe) mapping and the like. | 08-28-2014 |
20140234980 | DEVICES WITH A FLUID TRANSPORT NANOCHANNEL INTERSECTED BY A FLUID SENSING NANOCHANNEL AND RELATED METHODS - Devices, such as chips for DNA analysis, have at least one fluid transport nanochannel with at least one intersecting (e.g., transverse) sensing nanochannel that can be monitored for change in ionic current to determine characteristics or parameters of interest, e.g., molecular identification, length determination, localized (probe) mapping and the like. | 08-21-2014 |
20140234210 | METAL BISPHOSPHONATE NANOPARTICLES FOR ANTI-CANCER THERAPY AND IMAGING AND FOR TREATING BONE DISORDERS - Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents. | 08-21-2014 |
20140220682 | Isolation, Expansion and Use of Autologous Pluripotent Stem Cells - The present invention relates to methods of isolating and culturing autologous pluripotent stem (aPS) cells. The present invention also provides isolated aPS cells, populations of aPS cells and cultures of aPS cells. Further provided are culture media for expanding aPS cells and methods of culturing aPS cells. The invention also provides for the use of aPS cells, e.g., for diagnostics, drug evaluation and screening, and regenerative medicine. | 08-07-2014 |
20140206091 | CROSS-LINKING COMPOSITIONS AND RELATED METHODS OF ISOTOPE TAGGING OF INTERACTING PROTEINS AND ANALYSIS OF PROTEIN INTERACTIONS - An isotope labeled asymmetric cross-linker is provided for the detection of cross-linked peptides. A cross-linking and mass spectrometry strategy, referred to as isotope tagging of interacting proteins (iTIP), improves the specificity of detecting cross-linked peptides and accurate identification of the interacting peptide sequences via the incorporation of isotopic signatures that are readily observed in the MS/MS spectrum. Isotope tagged peptides can be identified using mass spectrometry based on doublet peaks in a spectrum. Spectra can be subjected to database search strategies available for the sequencing of linear or non-cross-linked peptides. | 07-24-2014 |
20140200277 | METHODS OF FACILITATING NEURAL CELL SURVIVAL USING NON-PEPTIDE AND PEPTIDE BDNF NEUROTROPHIN MIMETICS - Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule. | 07-17-2014 |
20140181976 | METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR DETECTING INJECTED MACHINE CODE - According to one aspect, the subject matter described herein includes a method for detecting injected machine code. The method includes extracting data content from a buffer. The method also includes providing an operating system kernel configured to detect injected machine code. The method further includes executing, using the operating system kernel, the data content on a physical processor. The method further includes monitoring, using the operating system kernel, the execution of the data content to determine whether the data content contains injected machine code indicative of a code injection attack. | 06-26-2014 |
20140171395 | Tunable Nitric Oxide-Releasing Macromolecules Having Multiple Nitric Oxide Donor Structures - Provided here are nitric oxide-releasing compounds that include at least two different NO donor functional groups of the same class. In some embodiments, such nitric oxide-releasing compounds are macromolecules such as dendrimer and co-condensed silica. Pharmaceutical compositions, wound dressings, kits and methods of treatments are also provided herein. | 06-19-2014 |
20140171339 | METHODS AND KITS FOR DETECTING ADENOMAS, COLORECTAL CANCER, AND USES THEREOF - This invention is directed to a novel method to detect adenomas and colorectal cancer (CRC) using a bacterial signature. Included in the invention are methods of (a) determining an individual's risk developing adenomas or CRC; (b) determine whether or not a patient should have a colonoscopy; (c) differential diagnosis; (d) staging; (e) selecting therapies; (f) monitoring therapies; (g) patient surveillance; and (h) drug screening. Kits and reagents for detecting adenomas and CRC and/or drug screening are also part of the invention. | 06-19-2014 |
20140141002 | Method for Inhibiting Cellular Activation by Insulin-Like Growth Factor-1 - A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described. | 05-22-2014 |
20140134646 | VITRO CAPTURE AND ANALYSIS OF CIRCULATING TUMOR CELLS - This invention provides methods and compositions for capturing circulating tumor cells (CTCs) as well as various divergent CTC phenotypes using seprase-specific affinity reagents. Methods of analyzing CTCs and assessing their metastatic potential in vivo and in vitro are also disclosed. | 05-15-2014 |
20140134321 | NITRIC OXIDE-RELEASING COATINGS - Provided according to embodiments of the invention are NO-releasing sol-gel coating formed from a sol precursor solution comprising a backbone alkoxysilane and a diazeniumdiolate-modified alkoxysilane. Further provided are methods of producing NO-releasing sol-gel coatings. Such methods may include (a) co-condensing a sol precursor solution comprising a backbone alkoxysilane and a diazeniumdiolate-modified alkoxysilane in a solvent to form a sol; (b) coating a substrate with the sol; and (c) drying the sol to form the NO-releasing sol-gel coating. | 05-15-2014 |
20140119496 | COMPACT MICROBEAM RADIATION THERAPY SYSTEMS AND METHODS FOR CANCER TREATMENT AND RESEARCH - The present subject matter relates to compact, non-synchrotron microbeam radiation therapy (MRT) systems and methods for cancer research and treatment based on a carbon nanotube distributed x-ray source array technology. The systems and methods can deliver microscopically discrete x-ray radiation at peak dose rate of 10 Gy per second or higher. The x-ray radiation can be provided by a spatially distributed x-ray source array. The technology can be used, for example and without limitation, for human cancer treatment, for intra-operative radiation therapy, and for pre-clinical cancer research on animal cancer models. | 05-01-2014 |
20140112906 | Prostatic Acid Phosphatase for the Treatment of Pain - Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase (“PAP”) polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice. Allodynia and hyperalgesia due to nerve injury can be prevented by increasing PAP activity in spinal cord. | 04-24-2014 |
20140112905 | Prostatic Acid Phosphatase for the Treatment of Pain - Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase (“PAP”) polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice. Allodynia and hyperalgesia due to nerve injury can be prevented by increasing PAP activity in spinal cord. | 04-24-2014 |
20140100224 | NEUROTROPHIN MIMETICS AND USES THEREOF - The present application is related to compounds which are novel neurotrophin mimetics. The application also discloses the treatment of disorders associated with p75 expression, such as degradation or dysfunction of cells expressing p75 in a mammal by administering an effective amount of such compounds. | 04-10-2014 |
20140094712 | APPARATUS AND METHODS FOR ACOUSTICALLY OR MECHANICALLY STIMULATING A COCHLEA AND INTRACOCHLEAR RECORDING OF MECHANICALLY OR ACOUSTICALLY EVOKED AUDITORY POTENTIALS IN THE COCHLEA - An apparatus for acoustic or mechanical stimulation of a cochlea and measurement of acoustically or mechanically evoked electrophysiologic responses from the cochlea is provided. In one example, the apparatus includes an acoustic stimulator for generating an acoustic signal and an electrophysiologic response measuring device positioned proximal the cochlea or within the cochlea for measuring an acoustically evoked electrophysiologic response to the acoustic signal. Methods of utilizing the apparatus for diagnostic and therapeutic procedures related to hearing impairment are also provided. | 04-03-2014 |
20140087458 | METHODS AND COMPOSITIONS FOR PRODUCING VITAMIN K DEPENDENT PROTEINS - The present invention relates to methods and compositions for improving the productivity of recombinant vitamin K dependent protein expression in host cells. | 03-27-2014 |
20140086835 | Methods and Compositions for Heptameric Targeting Ligands - The present invention provides a self assembly molecule having an affinity for one or more target molecules, for use in formation of a heptameric complex, comprising: a) a monomer comprising a multimerization domain of Archaeal Sm1 (AF-Sm1) protein or SM-like ribonucleoprotein from other organisms, able to interact with other molecules of the same monomer comprising a multimerization domain of AF-Sm1 protein or SM-like ribonucleoprotein to self-assemble into a heptamer; and b) a target binding domain or peptide attached directly or via a linker to the monomer of (a). Also provided are heptamers comprising these self assembly molecules and methods for their use in therapy, imaging and diagnostics. | 03-27-2014 |
20140081012 | NANOPARTICLE, LIPOSOMES, POLYMERS, AGENTS AND PROTEINS MODIFIED WITH REVERSIBLE LINKERS - Pharmaceutical, chemical and biological agents containing a reversible disulfide linker are described. These agents can also be covalently bound or contained in delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain an agent having a reversible disulfide linker and to vehicles that are covalently linked to the agent containing a reversible disulfide linker. The modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting while the reversibility of the linker can leave the agent to which it is attached free from residual chemical groups after being reduced. | 03-20-2014 |
20140072632 | METHODS FOR FABRICATING ISOLATED MICRO- OR NANO-STRUCTURES USING SOFT OR IMPRINT LITHOGRAPHY - The presently disclosed subject matter describes the use of fluorinated elastomer-based materials, in particular perfluoropolyether (PFPE)-based materials, in high-resolution soft or imprint lithographic applications, such as micro- and nanoscale replica molding, and the first nano-contact molding of organic materials to generate high fidelity features using an elastomeric mold. Accordingly, the presently disclosed subject matter describes a method for producing free-standing, isolated nanostructures of any shape using soft or imprint lithography technique. | 03-13-2014 |
20140072568 | MONOCLONAL ANTIBODIES FOR ENHANCING OR INHIBITING INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) - The present invention provides an antibody or antigen-binding fragment thereof that binds α | 03-13-2014 |
20140065200 | NITRIC OXIDE-RELEASING NANORODS AND THEIR METHODS OF USE - In one aspect, the subject matter disclosed herein is directed to NO-releasing functionalized nanorods having a desirable aspect ratio. The nanorods are also capable of releasing a desirable amount of NO (nitric oxide). In another aspect, the subject matter disclosed herein is directed to a composition comprising the NO-releasing nanorods. In another aspect, the subject matter disclosed herein is directed to methods of preparing NO-releasing nanorods having a specified aspect ratio. In another aspect, the subject matter disclosed herein is directed to a method of combating infection comprising administering to a subject a composition comprising NO-releasing nanorods, wherein the nanorods have a specified aspect ratio and NO-release profile. | 03-06-2014 |
20140058124 | NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS - The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications. | 02-27-2014 |
20140056854 | VIRAL VECTORS WITH MODIFIED TRANSDUCTION PROFILES AND METHODS OF MAKING AND USING THE SAME - The present invention provides AAV capsid proteins, virus capsids comprising said capsid proteins and virus vectors comprising said capsid proteins, wherein the AAV capsid proteins have one or more mutations, wherein the mutation(s) result in a phenotype of decreased liver transduction and/or reduced glycan binding affinity as compared to a control. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject. | 02-27-2014 |
20140044740 | Diagnostic and Therapeutic Targets for Leukemia - The present invention relates to methods of identifying candidate compounds for the treatment of leukemia and diagnostic methods based on histone methylation and HoxA5 promoter activity. | 02-13-2014 |
20140034505 | Ruthenium or Osmium Complexes and Their Uses as Catalysts for Water Oxidation - The present invention provides ruthenium or osmium complexes and their uses as a catalyst for catalytic water oxidation. Another aspect of the invention provides an electrode and photo-electrochemical cells for electrolysis of water molecules. | 02-06-2014 |
20140017121 | TERTIARY S-NITROSOTHIOL-MODIFIED NITRICOXIDE-RELEASING XEROGELS AND METHODS OF USING THE SAME - Provided according to embodiments of the invention are novel tertiary alkyl thiol compounds and novel tertiary alkyl nitrosothiol compounds. Further provided according to embodiments of the invention are methods of forming a nitric oxide (NO)-releasing xerogel coating that include (a) co-condensing a sol precursor solution comprising at least one backbone alkoxysilane and at least one tertiary thiol alkoxysilane in a solvent to form a sol; (b) coating a substrate with the sol; (c) optionally, drying the sol to form the xerogel coating; and (d) contacting the xerogel coating with a nitrosating agent. Methods of using xerogel coatings are also included. | 01-16-2014 |
20140014550 | MICROSAMPLE CRYOSTORAGE SYSTEMS AND METHODS - A multi-vial assembly for containing a plurality of samples in a cryostorage system includes a plurality of vials each defining a vial chamber to hold a respective sample and coupled together to form an integral vial assembly. The vials are independently removable from the integral vial assembly to permit selective access to the respective samples. | 01-16-2014 |
20140005426 | NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS | 01-02-2014 |
20140001146 | METHODS AND SYSTEMS FOR USING ACTUATED SURFACE-ATTACHED POSTS FOR BIOFLUID RHEOLOGY | 01-02-2014 |
20130345235 | PHENOXY THIOPHENE SULFONAMIDES AND THEIR USE AS INHIBITORS OF GLUCURONIDASE - This invention relates generally to compounds that are glucuronidase inhibitors. Glucuronidase inhibitors described include phenoxy thiophene sulfonamides. Other compounds, for instance pyridine sulfonyls, benzene sulfonyls, thiophene sulfonyls, thiazole sulfonyls, thiophene carbonyls, and thiazole carbonyls, are also contemplated. Also contemplated are compositions including one or more of such compounds for use inhibiting glucuronidase and methods of using one or more of such compounds as a co-drug to be used in combination with the anticancer drug CPT-11. | 12-26-2013 |
20130344334 | NITRIC OXIDE-RELEASING S-NITROSOTHIOL-MODIFIED SILICA PARTICLES AND METHODS OF MAKING THE SAME - Provided according to some embodiments of the invention are methods of forming co-condensed silica particles. In some embodiments, the methods include reacting a thiol-containing silane and a backbone alkoxysilane in a reaction solution that comprises water to form thiol-functionalized co-condensed silica particles, wherein the thiol-functionalized co-condensed silica particles include a polysiloxane matrix and at least some of thiol groups are present within the polysiloxane matrix; and reacting the thiol-functionalized co-condensed silica particles with a nitrosating agent to provide the S-nitrosothiol-functionalized co-condensed silica particles. In some embodiments, provided are S-nitrosothiol-functionalized co-condensed silica particles. | 12-26-2013 |
20130337504 | Methods and Compositions for Producing Active Vitamin K-Dependent Proteins - The present invention provides methods and compositions for the production of vitamin K dependent proteins. | 12-19-2013 |
20130336891 | FORMULATION OF ACOUSTICALLY ACTIVATABLE PARTICLES HAVING LOW VAPORIZATION ENERGY AND METHODS FOR USING SAME - Formulation of acoustically activatable particles having low vaporization energy and methods for using same are disclosed. According to one aspect, a method of producing particles of materials includes, with a first substance that includes at least one component that is a gas at room temperature and atmospheric pressure, performing one of: causing the first substance to condense to a liquid phase, and extruding or emulsifying the first substance into or in the presence of a second substance to create a droplet or emulsion in which the first substance is encapsulated by the second substance; or extruding or emulsifying the first substance into or in the presence of a second substance to create a bubble in which the first substance is encapsulated by the second substance and wherein at least some of the first substance is in a gaseous phase, and causing the first substance to condense to a liquid phase, which causes the bubble to transform into a droplet or emulsion. The droplet or emulsion so created is an activatable phase change agent that is stable at room temperature and pressure. | 12-19-2013 |
20130336884 | NANOPARTICLE FABRICATION METHODS, SYSTEMS, AND MATERIALS FOR FABRICATING ARTIFICIAL RED BLOOD CELLS - A plurality of artificial red blood cell particles includes each particle of the plurality being substantially monodisperse and each particle having a largest common linear dimension of about 5 μm to about 10 μm. The particles can also have a modulus configured such that a particle of the plurality of particles can pass through a tube having an inner diameter of less than about 3 μm. | 12-19-2013 |
20130330700 | MODULAR STAGED REALITY SIMULATOR - This invention is directed to a modular staged simulator and a process of simulating medical trauma and maladies for the purpose of training or certifying individuals including medical professionals. More specifically, this disclosure relates to ex vivo training exercises as opposed to traditional forms of training using intact cadavers, in vivo surgery on animal subjects; and supervised apprenticeship performing surgery on human subjects with trauma or maladies under the watch of a skilled medical practitioner. | 12-12-2013 |
20130327936 | MICROCHIPS WITH INTEGRATED MULTIPLE ELECTROSPRAY IONIZATION EMITTERS AND RELATED METHODS, SYSTEMS AND DEVICES - Microchips which are particularly suitable for use with a mass spectrometer include a microchip body with at least one fluid channel formed into the microchip body and at least two flat monolithic closely spaced integrated ESI (electrospray ionization) emitters defined by shaped projections formed to extend from one side of the microchip body, a respective one being in fluid communication with a fluid channel. Related systems and methods are also described. | 12-12-2013 |
20130309211 | Wnt1 for Treatment of Cardiovascular Disorders and Injuries - The present invention relates to the discovery of the role of Wnt1 in multiple cardiovascular processes, including cardiac repair, angiogenesis, and stimulation of endothelial progenitor cells. This discovery provides methods of using Wnt1 to treat cardiovascular disorders and injuries. | 11-21-2013 |
20130303543 | PROTECTION OF RENAL TISSUES FROM ISCHEMIA THROUGH INHIBITION OF THE PROLIFERATIVE KINASES CDK4 AND CDK6 - The presently disclosed subject matter relates to methods and compositions for protecting cells and or tissues from damage due to ischemia. In particular, the presently disclosed subject matter relates to the protective action of cyclin dependent kinase 4/6 (CDK4/6) lithibitors administered to subjects that have been exposed to, or that are at risk of, ischemia. | 11-14-2013 |
20130296540 | CHEMOENZYMATIC SYNTHESIS OF STRUCTURALLY HOMOGENEOUS ULTRA-LOW MOLECULAR WEIGHT HEPARINS - Methods for preparing synthetic heparins are provided. Synthetic heparin compounds, including ultralow molecular weight heparin compounds are provided. Also provided are methods of chemoenzymatically synthesizing structurally homogeneous ultra-low molecular weight heparins. Heparin compounds provided herein can have anticoagulant activity. | 11-07-2013 |
20130252325 | Duplexed Parvovirus Vectors - The present invention provides duplexed parvovirus vector genomes that are capable under appropriate conditions of forming a double-stranded molecule by intrastrand base-pairing. Also provided are duplexed parvovirus particles comprising the vector genome. Further disclosed are templates and methods for producing the duplexed vector genomes and duplexed parvovirus particles of the invention. Methods of administering these reagents to a cell or subject are also described. Preferably, the parvovirus capsid is an AAV capsid. It is further preferred that the vector genome comprises AAV terminal repeat sequences. | 09-26-2013 |
20130249138 | HIGH FIDELITY NANO-STRUCTURES AND ARRAYS FOR PHOTOVOLTAICS AND METHODS OF MAKING THE SAME - A photovoltaic device includes an electron accepting material and an electron donating material. One of the electron accepting or donating materials is configured and dimensioned as a first component of a bulk heterojunction with a predetermined array of first structures, each first structure is substantially equivalent in three dimensional shape, has a substantially equivalent cross-sectional dimension, and where each first structure of the array of first structures has a substantially equivalent orientation with respect to adjacent first structures of the predetermined array forming a substantially uniform array. | 09-26-2013 |
20130237732 | SYNTHESIS OF PARA-XYLENE AND TOLUENE - A method of making para-xylene or toluene is carried out by: (a) reacting a C5 or C6 linear monoene (itself, or formed from a C5 or C6 linear alkane) with a hydrogen acceptor in the presence of a hydrogen transfer catalyst to produce a C5 or C6 diene; (b) reacting the C5-C6 diene with ethylene to produce a cyclohexene having 1 or 2 methyl groups substituted thereon; and then (c) either (i) dehydrogenating the cyclohexene in the presence of a hydrogen acceptor with a hydrogen transfer catalyst to produce a compound selected from the group consisting of para-xylene and toluene, or (ii) dehydrogenating the cyclohexene in the absence of a hydrogen acceptor with a dehydrogenation catalyst, to produce para-xylene or toluene. | 09-12-2013 |
20130237445 | METHODS AND KITS FOR DETECTING MELANOMA - This invention is directed to a method for detecting melanoma in a tissue sample by measuring a level of methylation of one or more regulatory elements differentially methylated in melanoma and benign nevi. The invention provides methods for detecting melanoma, related kits, and methods of screening for compounds to prevent or treat melanoma. | 09-12-2013 |
20130228950 | METHODS AND MATERIALS FOR FABRICATING MICROFLUIDIC DEVICES - Materials and methods are provided for fabricating microfluidic devices. The materials include low surface energy fluoropolymer compositions having multiple cure functional groups. The materials can include multiple photocurable and/or thermal-curable functional groups such that laminate devices can be fabricated. The materials also substantially do not swell in the presence of hydrocarbon solvents. | 09-05-2013 |
20130225665 | MICRORNAS THAT REGULATE MUSCLE CELL PROLIFERATION AND DIFFERENTIATION - The presently disclosed subject matter provides methods and compositions for modulating gene expression in myocytes. Also provided are cells comprising the compositions of the presently disclosed subject matter. | 08-29-2013 |
20130225658 | MICRORNAS THAT REGULATE MUSCLE CELL PROLIFERATION AND DIFFERENTIATION - The presently disclosed subject matter provides methods and compositions for modulating gene expression in myocytes. Also provided are cells comprising the compositions of the presently disclosed subject matter. | 08-29-2013 |
20130225629 | TARGETING PI3K/MTOR SIGNALLING AND NEUTROPHIL RECRUITMENT FOR TREATMENT OF ENTERITIS - The presently disclosed subject matter generally relates to methods and compositions for treating enteritis. More particularly, the presently disclosed subject matter relates to methods and compositions for modulating a component of a PI3K/mTOR pathway. In some embodiments, the methods and compositions of the presently disclosed subject matter generally relates to the treatment of campylobacteriosis. More particularly, the methods and compositions of the presently disclosed subject matter relate to the treatment of campylobacteriosis by modulating a component of a PI3K/mTOR pathway. | 08-29-2013 |
20130225479 | Methods and Compositions for Treating Inflammation - The present invention provides methods and compositions for treating inflammation and inflammatory disorders in a subject, by administering an effective amount of KSHV-Orf63 and/or active peptides and/or fragments thereof. | 08-29-2013 |
20130209438 | Prostatic Acid Phosphatase for the Treatment of Pain - Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase (“PAP”) polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice. Allodynia and hyperalgesia due to nerve injury can be prevented by increasing PAP activity in spinal cord. | 08-15-2013 |
20130203799 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS - Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors. | 08-08-2013 |
20130197924 | METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR EVALUATING A HOSPITAL PATIENT'S RISK OF MORTALITY - A method for evaluating a hospital patient's risk of mortality includes collecting data from physiologic signals generated by patient monitors, physiologic signals of organ function, and demographic information for a patient. A measure of the variability of at least one of the physiologic signals is determined. Data and the measure of variability are analyzed to determine whether a value for a particular physiologic or demographic variable falls within a critical interval for the variable that indicates that the value is predictive of mortality or survival. Each time a value for a physiological or demographic variable for the patient falls within a critical interval, the occurrence of an event for the patient is recorded. The number of events for the patient is counted over a time period. Output perceptible by human user that indicates the patient's risk of mortality or likelihood of survival is generated based on the count. | 08-01-2013 |
20130196867 | COMBINATORIAL POST-TRANSLATIONALLY-MODIFIED HISTONE PEPTIDES, ARRAYS THEREOF, AND METHODS OF USING THE SAME - The present invention generally relates to combinatorial post-translationally-modified histone peptides and arrays thereof. The invention further relates to methods of using the same. | 08-01-2013 |
20130195811 | Biomatrix Scaffolds - The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same. | 08-01-2013 |
20130177921 | Detection of Damage to DNA - The present invention relates to methods of assessing damage to cellular DNA including the type, frequency and/or distribution of the DNA damage in the genome. The invention further provides methods of evaluating DNA damage in a cell caused by an agent and/or event as well as methods of determining a subject's prior exposure to an agent and/or event that is known or suspected to cause DNA damage. Further provided are methods of determining whether a subject is at an increased risk for a disease or disorder as a result of cellular DNA damage. | 07-11-2013 |
20130177598 | DISCRETE SIZE AND SHAPE SPECIFIC PHARMACEUTICAL ORGANIC NANOPARTICLES - A pharmaceutical composition comprising protein micro and/or nanoparticles are provided. The particles have a predetermined geometric shape and a broadest dimension less than about 10 micrometers. The particles may further comprise active agents. | 07-11-2013 |
20130137176 | Biomatrix Scaffolds for Industrial Scale Dispersal - The present invention provides biomatrix scaffolds for industrial scale dispersal. | 05-30-2013 |
20130131678 | THREADED ELASTIC INTRAMEDULLARY NAILS DEVICES AND METHODS - Devices and methods for treating fractures using intramedullary nails and screws are provided. An intramedullary nail and fixation device can be capable of holding a bone out to length when it is broken in a manner that allows shortening of and/or compressing a bone to promote healing. The device can include a flexible nail with a first leading end and a second end, the nail having a threaded outer surface along at least a portion of a length of the nail. A method for treatment of fractures of long bones having a medullary canal can include creating a hole into an end of a bone to be compressed, inserting a leading end of such a flexible nail into the hole, and rotating the nail to advance the nail through the medullary canal. | 05-23-2013 |
20130125714 | SCREW HOLDER-DRIVER APPARATUSES, SYSTEMS AND METHODS - Screw driver-holder apparatuses, systems and methods are provided and can include a screw and a screwdriver. The screw can include a threaded screw body and a screw head, and the screw head can include a socket and a screw head surface surrounding the socket. The screwdriver can include a hollow sleeve with a longitudinal bore and a first end defining a screw engagement surface and a driving shaft positioned within the longitudinal bore of the hollow sleeve and rotatable relative to the hollow sleeve. The driving shaft can further include a first end extending beyond the first end of the hollow sleeve, a second end opposite the first end, and a stop restricting axial movement of the sleeve towards the second end of the driving shaft. The first end can include a protruding tip adapted for engaging the socket of the screw head. | 05-23-2013 |
20130123097 | SUPPORTED IRIDIUM CATALYSTS - A method of converting at least one first alkane to a mixture of at least one low molecular weight alkane (optionally also including additional lower and/or higher molecular weight alkanes) and at least one high molecular weight alkane, comprises: reacting a first alkane in the presence of dual catalyst system comprising a first catalyst (i.e., a hydrogen transfer catalyst) and a second catalyst (i.e., a metathesis catalyst) to produce a mixture of low and high molecular weight alkanes. | 05-16-2013 |
20130115271 | PREDICTORS OF PHARMACOKINETIC AND PHARMACODYNAMIC DISPOSITION OF CARRIER-MEDIATED AGENTS - The invention provides a method of predicting the clearance rate of a carrier-mediated agent and/or the release of an agent from a carrier in a subject comprising measuring the number and/or activity of phagocytic cells and/or the amount and/or activity of opsonins and/or the amount and/or activity of complement within a biological sample obtained from a subject, and predicting the clearance rate of the carrier-mediated agent and/or the release of the agent from the carrier based upon the number and/or activity of the phagocytic cells and/or the amount and/or activity of opsonins and/or the amount and/or activity of complement. | 05-09-2013 |
20130102946 | Hemostatic Textile - The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal fibers; flax fibers; soybean fibers; corn fibers; hemp fibers; lyocel fibers; wool; lactide and/or glycolide polymers; lactide/glycolide copolymers; silicate fibers; polyamide fibers; feldspar fibers; zeolite fibers, zeolite-containing fibers, acetate fibers; and combinations thereof; the hemostatic textile capable of activating hemostatic systems in the body when applied to a wound. Additional cofactors such as thrombin and hemostatic agents such as RL platelets, RL blood cells; fibrin, fibrinogen, and combinations thereof may also be incorporated into the textile. The invention is also directed to methods of producing the textile, and methods of using the textile to stop bleeding. | 04-25-2013 |
20130101505 | Stable Activatable Particles as Radiotherapeutic Agents for the Treatment of Disease - The present invention provides radiotherapeutic agents and compositions and methods for making and using the same. In some embodiments, the radiotherapeutic agent is a nanoparticle comprising a radionuclide and a carrier moiety. In some embodiments, the radionuclide is produced by activating a stable activatable particle via neutron activation. | 04-25-2013 |
20130085106 | METHODS AND FORMULATIONS FOR OXYTOCIN TREATMENT OF SUBSTANCE USE, PSYCHIATRIC AND OTHER DISORDERS - The invention provides a method of treating a psychiatric or medical disorder in a mammalian subject, the method comprising administering to the subject an effective amount of an oxytocin receptor agonist (e.g., oxytocin). Optionally, the oxytocin receptor agonist is delivered by intranasal administration. Further provided is a method of increasing social cognition, increasing social functioning, increasing empathy, increasing trust of others, reducing paranoia and/or reducing hostility in a subject with a psychotic disorder, a mood disorder characterized by psychotic features, a personality disorder or a pervasive developmental disorder, the method comprising administering to the subject an effective amount of an oxytocin receptor agonist. The invention also contemplates a method of preventing opioid dependence, opioid tolerance and/or opioid withdrawal symptoms in a subject receiving opioid treatment for pain relief, the method comprising administering to the subject an effective amount of an oxytocin receptor agonist. The invention also provides pharmaceutical compositions comprising an effective amount of an oxytocin receptor agonist and a pharmaceutically acceptable carrier. | 04-04-2013 |
20130084575 | METHOD AND DEVICE FOR REPLICATING A CELL COLONY IN CULTURE FOR EARLY ANALYSIS - The present invention provides an apparatus comprising, in combination: (a) a cell culture plate, the cell culture plate comprising a first substrate and a plurality of cell carriers on the substrate in a first pattern; and (b) a cell replication plate, the cell replication plate comprising a second substrate and a plurality of cell sampling posts on the second substrate in a second pattern corresponding to the first pattern. Each of the sampling posts is configured to align with a respective one of the cell carriers in a position in which cells growing on the cell carrier propagate onto the sampling post; so that a plurality of distinct cell colonies growing on the cell culture plate are replicated on the cell replication plate. Methods of using the same are also described. | 04-04-2013 |
20130079417 | Highly Selective 5-HT(2C) Receptor Agonists That Show Anti-Psychotic Effects with Antagonist Activity at the 5-HT(2B) Receptor - Highly selective 5-HT(2C) receptor agonists receptors are disclosed. The 5-HT(2C) receptor agonists are used in the treatments of disease and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders. | 03-28-2013 |
20130072842 | Hemostatic Textile - The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal fibers; flax fibers; soybean fibers; corn fibers; hemp fibers; lyocel fibers; wool; lactide and/or glycolide polymers; lactide/glycolide copolymers; silicate fibers; polyamide fibers; feldspar fibers; zeolite fibers, zeolite-containing fibers, acetate fibers; and combinations thereof; the hemostatic textile capable of activating hemostatic systems in the body when applied to a wound. Additional cofactors such as thrombin and hemostatic agents such as RL platelets, RL blood cells; fibrin, fibrinogen, and combinations thereof may also be incorporated into the textile. The invention is also directed to methods of producing the textile, and methods of using the textile to stop bleeding. | 03-21-2013 |
20130068690 | ADSORPTION DEVICES, SYSTEMS AND METHODS - Adsorption devices, systems, and methods are provided. In one embodiment, an adsorption device includes a fabric and an adsorbing complex attached at least partially attached to a surface of the fabric, the adsorbing complex being reactive to selectively adsorb a substance from a liquid passing through the fabric to remove at least a portion of the substance from the liquid. In one embodiment, the adsorption device can be incorporated into an extracorporeal blood circuit adapted to filter phosphate from blood of a hemodialysis patient without altering chemistry of the blood. | 03-21-2013 |
20130060540 | SYSTEMS AND METHODS THAT GENERATE HEIGHT MAP MODELS FOR EFFICIENT THREE DIMENSIONAL RECONSTRUCTION FROM DEPTH INFORMATION - Methods of generating a three dimensional representation of an object in a reference plane from a depth map including distances from a reference point to pixels in an image of the object taken from a reference point. Weights are assigned to respective voxels in a three dimensional grid along rays extending from the reference point through the pixels in the image based on the distances in the depth map from the reference point to the respective pixels, and a height map including an array of height values in the reference plane is formed based on the assigned weights. An n-layer height map may be constructed by generating a probabilistic occupancy grid for the voxels and forming an n-dimensional height map comprising an array of layer height values in the reference plane based on the probabilistic occupancy grid. | 03-07-2013 |
20130053433 | FATTY ACID DERIVATIVES AND ANALOGS OF DRUGS - The present disclosure is directed to fatty acid-drug conjugates, the preparation and use thereof and long-chain (C | 02-28-2013 |
20130040317 | CELL LINES COMPRISING ENDOGENOUS TASTE RECEPTORS AND THEIR USES - Provided herein are cell lines and assays that can be utilized to identify taste receptor modulators. | 02-14-2013 |
20130040316 | CELL LINES COMPRISING ENDOGENOUS TASTE RECEPTORS AND THEIR USES - Provided herein are cell lines and assays that can be utilized to identify taste receptor modulators. | 02-14-2013 |
20130024136 | METHODS, SYSTEMS AND COMPUTER READABLE MEDIA FOR APPLYING MULTI-PUSH ACOUSTIC RADIATION FORCE TO SAMPLES AND MONITORING A RESPONSE TO QUANTIFY MECHANICAL PROPERTIES OF SAMPLES - A method for evaluating mechanical properties of a sample includes applying a plurality of pulses of acoustic energy to a sample to apply a mechanical force to the sample and induce a non-steady-state displacement in the sample. The method further includes monitoring a response of the sample caused by the application of the mechanical force. The method further includes determining a quantitative value for a mechanical property of the sample based on the response. | 01-24-2013 |
20130011618 | PHOTOCURABLE PERFLUOROPOLYETHERS FOR USE AS NOVEL MATERIALS IN MICROFLUIDIC DEVICES - A functionalized photocurable perfluoropolyether is used as a material for fabricating a solvent-resistant microfluidic device. Such solvent-resistant microfluidic devices can be used to control the flow of small amounts of a fluid, such as an organic solvent, and to perform microscale chemical reactions that are not amenable to other polymer-based microfluidic devices. | 01-10-2013 |
20120329066 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS - Although it can be farnesylated, mutant lamin A expressed in Hutchinson Gilford Progeria Syndrome cannot be defarnesylated; the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (“progerin”) that alters normal lamin A function as a dominant negative, and assumes its own aberrant function through its association with the nuclear membrane. Retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) will inhibit formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with FTIs. | 12-27-2012 |
20120322797 | SELECTIVE BETA-GLUCURONIDASE INHIBITORS AS A TREATMENT FOR SIDE EFFECTS OF CAMPTOTHECIN ANTINEOPLASTIC AGENTS - Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial β-glucuronidases and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds. | 12-20-2012 |
20120322114 | ENZYMATIC SYNTHESIS OF SULFATED POLYSACCHARIDES - Heparosan is sulfated at the iduronic acid residue by providing a reaction mixture comprising C5 epimerase to convert glucuronic acid to iduronic acid, and at least one O-sulfotransferase (OST) enzyme and 3′-phosphoadenosine 5′-phosphosulfate (PAPS). | 12-20-2012 |
20120278477 | METHODS, SYSTEMS, AND COMPUTER PROGRAM PRODUCTS FOR NETWORK SERVER PERFORMANCE ANOMALY DETECTION - Methods, systems, and computer readable media for network server performance anomaly detection are disclosed. According to one aspect of the subject matter disclosed, a method is disclosed for real-time computation of an endpoint performance measure based on transport and network layer header information. The method includes passively collecting transport and network layer header information from packet traffic in a network. Connections in the network are modeled using an abstract syntax for characterizing a sequence of application-level bidirectional interactions between endpoints of each connection and delays between the interactions. Application-level characteristics of the packet traffic are determined based on the modeled connections. A performance measure of at least one endpoint is computed based on the application-level characteristics and the modeled connections. | 11-01-2012 |
20120264811 | Elongator Proteins and Use Thereof as DNA Demethylases - The invention provides DNA demethylases comprising Elp1, Elp2, Elp3, Elp4, Elp5 and/or Elp6. The invention also provides methods of modulating gene expression, for example, for the treatment of cancer or to modify the cellular transcription program (e.g., for regenerative medicine). Also provided are methods of identifying compounds that modulate the DNA demethylase activity of the DNA demethylases of the invention. | 10-18-2012 |
20120259153 | DELIVERY SYSTEMS FOR BRACHYTHERAPY, AND ASSOCIATED METHODS - Delivery systems adapted for implementation during a brachytherapy procedure are provided. The delivery system includes a plurality of brachytherapy seeds and a plurality of spacers. Each spacer is formed of a matrix material carrying a plurality of microparticles and/or nanoparticles. The microparticles and/or nanoparticles carry an agent and are biodegradable and/or biocompatible. The brachytherapy seeds and the spacers are configured to be delivered to a target site. Associated methods are also provided. | 10-11-2012 |
20120256354 | METHODS AND MATERIALS FOR FABRICATING MICROFLUIDIC DEVICES - Materials and Methods are provided for fabricating microfluidic devices. The materials include low surface energy fluoropolymer compositions having multiple cure functional groups. The materials can include multiple photocurable and/or thermal-curable functional groups such that laminate devices can be fabricated. The materials also substantially do not swell in the presence of hydrocarbon solvents. | 10-11-2012 |
20120201872 | LIPOSOMES COMPRISING A CALCIUM PHOSPHATE-CONTAINING PRECIPITATE - Provided herein are methods and compositions for the delivery of bioactive compounds to a cell, tissue, or physiological site. The compositions comprise delivery system complexes comprising liposomes encapsulating a biodegradable ionic precipitate having incorporated therein a bioactive compound and delivery system complexes comprising a biodegradable ionic precipitate ionically bound to a surrounding lipid bilayer, wherein the biodegradable ionic precipitate comprises a bioactive compound. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes comprising bioactive compounds that have therapeutic activity against the disease or unwanted condition to the subject. | 08-09-2012 |
20120172776 | HEMOSTATIC TEXTILE - The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal fibers; flax fibers; soybean fibers; corn fibers; hemp fibers; lyocel fibers; wool; lactide and/or glycolide polymers; lactide/glycolide copolymers; silicate fibers; polyamide fibers; feldspar fibers; zeolite fibers, zeolite-containing fibers, acetate fibers; and combinations thereof; the hemostatic textile capable of activating hemostatic systems in the body when applied to a wound. Additional cofactors such as thrombin and hemostatic agents such as RL platelets, RL blood cells; fibrin, fibrinogen, and combinations thereof may also be incorporated into the textile. The invention is also directed to methods of producing the textile, and methods of using the textile to stop bleeding. | 07-05-2012 |
20120142108 | Compositions For Treating Bacterial Infections - Polynucleotides encoding a mutant human carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing cells to a prodrug agent, inhibiting cell growth, treating drug addiction, and facilitating the metabolism of an organophosphate with this enzyme are also provided. In addition, a screening assay for identification of drugs activated by this enzyme is described. | 06-07-2012 |
20120114554 | Engineered Aerosol Particles, And Associated Methods - An engineered aerosol particle for use in aerosol applications is provided. The engineered aerosol particle comprises a fabricated nanoparticle body member being non-spherical. The fabricated nanoparticle body member is configured to provide at least one of auto-rotation, tumbling, or lift when entrained in an airstream to thereby increase settling time of the fabricated nanoparticle body member. An associated method is also provided. | 05-10-2012 |
20120064075 | CHIMERIC FACTOR VII MOLECULES WITH ENHANCED HALF LIFE AND METHODS OF USE - The present invention relates to novel proteins and methods of using chimeric Factor VIIa polypeptides. | 03-15-2012 |
20120034169 | NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS - The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications. | 02-09-2012 |
20120021055 | NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS - The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications. | 01-26-2012 |
20120009268 | Modified Virus Vectors and Methods of Making and Using the Same - The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. In particular embodiments, the modification comprises a substitution of one or more amino acids at amino acid positions 585 to 590 (inclusive) of the native AAV2 capsid protein sequence or the corresponding positions of other AAV capsid proteins. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo. | 01-12-2012 |
20110306878 | INTERVENTIONAL DRUG DELIVERY SYSTEM AND ASSOCIATED METHODS - A delivery system for local drug delivery to a target site of internal body tissue is provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A reservoir is configured to be disposed such that the reservoir is capable of interacting with the localized electric field. The reservoir is configured to carry a cargo capable of being delivered to the target site when exposed to the localized electric field. Associated methods are also provided. | 12-15-2011 |
20110301228 | GENE THERAPY VECTOR FOR TREATMENT OF STEROID GLAUCOMA - The presently disclosed subject matter provides an inducible vector comprising a therapeutic gene. In some embodiments a method is provided for treating steroid glaucoma. In some embodiments a method is provided for preventing elevated intraocular pressure in a subject receiving steroid treatment. In some embodiments a method is provided for reversing elevated intraocular pressure in a subject receiving steroid treatment. In some embodiments a steroid treatment method is provided. Also provided are pharmaceutical compositions comprising an inducible vector. | 12-08-2011 |
20110284805 | PRODUCTION OF MECHANICALLY EXFOLIATED GRAPHENE AND NANOPARTICLE COMPOSITES COMPRISING SAME - A method for producing nanospacer-graphene composite materials (i.e., mechanically-exfolitated graphene), wherein the graphene sheets are interspersed with nanospacers, thereby maintaining the 2D characteristics of the graphene sheets. The nanospacer-graphene composite material is highly porous, has a high surface area and is highly electrically conductive and may be optically transparent. | 11-24-2011 |
20110264030 | DELIVERY APPARATUS AND ASSOCIATED METHOD - A delivery apparatus for delivering a cargo to a target site of internal body tissue is provided. The delivery apparatus comprises a flexible tubular member having a distal end adapted for insertion proximate to the target site. A first electrode is configured for insertion within the flexible tubular member such that the first electrode is capable of being disposed proximate to the target site. A second electrode is configured to cooperate with the first electrode to form an electric field. A delivery component has a cargo carried thereby and is coupled with the first electrode. The delivery component is configured to degrade when exposed to the electric field such that the cargo is released to the target site upon degradation thereof. An associated method is also provided. | 10-27-2011 |
20110195030 | NANOPARTICLE COMPOSITIONS COMPRISING LIQUID OIL CORES - Nanocapsule and nanoemulsion particle compositions having improved physical and pharmacological properties are provided. The nanocapsule or nanoemulsion particle composition can comprise a pharmaceutically acceptable liquid oil phase, a surfactant, and optionally a co-surfactant. The liquid oil phase can comprise a monoglyceride, a diglyceride, a triglyceride, a propylene glycol ester, or a propylene glycol diester. In certain embodiments, the nanocapsule or nanoemulsion particle composition can be lyophilized and subsequently re-hydrated without increasing the mean particle size and/or adversely affecting the potency or efficacy of a therapeutic agent (e.g., paclitaxel) present in the nanocapsules or nanoemulsion particles. | 08-11-2011 |
20110186789 | SYNTHESIS OF GRAPHENE SHEETS AND NANOPARTICLE COMPOSITES COMPRISING SAME - A method for producing isolatable and dispersible graphene sheets, wherein the graphene sheets may be tailored to be soluble in aqueous, non-aqueous or semi-aqueous solutions. The water soluble graphene sheets may be used to produce a metal nanoparticle-graphene composite having a specific surface area that is 20 times greater than aggregated graphene sheets. Graphene sheets that are soluble in organic solvents may be used to make graphene-polymer composites. | 08-04-2011 |
20110172295 | METHODS AND COMPOSITIONS FOR THE REGULATION OF microRNA PROCESSING - Provided herein are methods and compositions for the regulation of microRNA processing. The invention presents methods for inhibiting the activity of a Lin-28-like polypeptide and methods for treating a subject with cancer comprising administering to a subject with cancer a compound that inhibits the activity of a Lin-28-like polypeptide. Compositions comprise isolated polynucleotides and expression cassettes comprising the same that promote the processing of at least one of a regulated primary microRNA transcript by Drosha and a regulated precursor microRNA by Dicer when introduced into or expressed in a cell. Compositions and methods are also provided for the selective suppression of target polynucleotides by a microRNA based on the level of expression of a Lin-28-like polypeptide within a cell. | 07-14-2011 |
20110165141 | Compositions for treating bacterial infections - Polynucleotides encoding a mutant human carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing cells to a prodrug agent, inhibiting cell growth, treating drug addiction, and facilitating the metabolism of an organophosphate with this enzyme are also provided. In addition, a screening assay for identification of drugs activated by this enzyme is described. | 07-07-2011 |
20110152229 | BETULINIC ACID DERIVATIVES AS ANTI-HIV AGENTS - The present invention provides compounds of the general structure: | 06-23-2011 |
20110123446 | DEGRADABLE COMPOUNDS AND METHODS OF USE THEREOF, PARTICULARLY WITH PARTICLE REPLICATION IN NON-WETTING TEMPLATES - The present invention provides compounds that will degrade under specified conditions, methods of using such compounds, and compositions comprising such compounds. The degradable compounds of the invention may be characterized by the labile —Si-A-C— groups present in the compounds (A representing an atom, such as O, N, or S, or a group, such as C═O). The compounds may be incorporated into a composition that further may include a polymeric matrix and/or a cargo component. A wide variety of cargo components may also be used in the present invention. In particular embodiments, the cargo component comprises a drug or other therapeutic agent. Accordingly, the invention particularly provides pharmaceutical formulations and methods of delivering a drug or other therapeutic material. | 05-26-2011 |
20110104139 | ANGIOSTATIC COMPOSITIONS COMPRISING TRUNCATED TYROSYL-tRNA SYNTHETASE POLYPEPTIDES AND METHODS OF USING SAME - Angiostatic compositions are provided comprising truncated forms of tyrosyl tRNA synthetase polypeptides. Also provided are methods of using such compositions in the treatment of conditions that benefit from decreased angiogenesis and/or neovascularization. | 05-05-2011 |
20110027806 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS - Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors. | 02-03-2011 |
20100286280 | INHIBITORS OF EPPIN/SEMENOGELIN BINDING AS MALE CONTRACEPTIVES - Compounds suitable for use in providing male contraception, an assay method for identifying such compounds, and methods of providing contraception using the compounds, are provided. The compounds described herein inhibit Eppin-semenogelin binding, and inhibit forward motility of sperm in humans and other primates. The assays identify compounds which both inhibit eppin-semenogelin binding and inhibit sperm motility, and can be carried out in a high throughput manner, using labeled recombinant Eppin and semenogelin. The compounds can be used in oral or transdermal compositions to temporarily and reversibly inhibit male fertility. They can also be used in addition to, or in place of, spermicides in spermicidal compositions, such as those used in conjunction with condoms, diaphragms, and spermicidal jellies. | 11-11-2010 |
20100272712 | JNK3 AS A TARGET FOR THE TREATMENT OF ANGIOGENESIS-RELATED DISEASES - Provided herein are methods for treating a subject having or at risk for an angiogenesis-related disorder. The methods include administering to the subject a therapeutically effective amount of an agent that inhibits JNK3 expression, or a therapeutically effective amount of an agent that inhibits JNK3 activity. Disorders that can be treated by these methods include cancer, rheumatoid arthritis, vascular diseases, and other disorders resulting from excessive angiogenesis. The therapeutic agent may be a compound, small molecule, peptide, antibody, antisense nucleic acid, ribozyme, or the like. Methods of identifying a candidate agent that modulates JNK3 expression are also provided. | 10-28-2010 |
20100196277 | NANOPARTICLE COMPOSITIONS FOR CONTROLLED DELIVERY OF NUCLEIC ACIDS - Micro- and nano-particles are molded in micro- and nano-scale molds fabricated from non-wetting, low surface energy polymeric materials. The micro- and nano-particles can include pharmaceutical compositions, biologic drugs, drug compositions, organic materials, RNA, DNA, oligonucleotides, and the like. | 08-05-2010 |
20100196256 | TITANIA NANOSHEETS DERIVED FROM ANATASE DELAMINATION - A novel titania nanosheet material synthesized using a novel mechanism using titania nanotubes as a starting material is described. The novel nanosheet material may be useful for many coating applications where titania nanoparticles are traditionally deposited including, but not limited to, self-cleaning coatings, gas sensors, hydrogen production, photocatalytic solar cells, and batteries. | 08-05-2010 |
20100190703 | PEPTIDES SPECIFIC FOR HUMAN BLOOD OUTGROWTH ENDOTHELIAL CELLS - Provided herein are compositions and methods for binding outgrowth endothelial cells (OEC). The compositions consist of peptide ligands capable of binding OEC with high affinity and specificity. The compositions of the invention include peptides set forth in SEQ ID NO: 1-38 and variants and derivatives thereof. Compositions also include the nucleotide sequences encoding the peptides of the invention. The compositions find use in methods for the isolation of OEC and for the recruitment and retention of OEC to sites of therapeutic interest. Methods for the identification and isolation of other peptides capable of binding OEC are also provided. | 07-29-2010 |
20100178278 | FORMABLE BIOCERAMICS - A formable bioceramic including hydroxyapatite nanocrystals, gelatin, and sol-gel-containing material is described. Also described is a process for making and using the bioceramic. The formable bioceramic displays superior mechanical strength, elasticity, biocompatibility and forming capabilities and is targeted for bone repairs and template-assisted tissue engineering applications. | 07-15-2010 |
20100150930 | MAGE-11 AS A MARKER FOR ENDOMETRIAL RECEPTIVITY TO EMBRYO TRANSPLANTATION AND A MARKER AND THERAPEUTIC TARGET IN CASTRATION-RECURRENT PROSTATE CANCER - Compositions and methods for determining endometrial receptivity to embryo implantation and for detecting and treating castration-recurrent prostate cancer are provided. The methods comprise measuring the level of melanoma antigen gene protein-11 (MAGE-11, also referred to as MAGE-Al 1) in an endometrial or prostate tissue sample. The level of MAGE-11 protein or mRNA can be correlated to endometrial receptivity to embryo implantation in a female human or nonhuman primate, or to the presence of castration-recurrent prostate cancer in a male patient in need thereof. Methods are described whereby MAGE-11 may serve as a target for vaccine development in the treatment of castration-recurrent prostate cancer. Methods for monitoring endometrial maturation, for diagnosing infertility, and for in vitro fertilization in a female human or nonhuman primate are also provided. Compositions of the invention include antibodies that specifically bind MAGE-11 and oligonucleotide primers useful for detecting MAGE-11 mRNA, as well as kits containing such antibodies or primers. | 06-17-2010 |
20100147365 | HIGH FIDELITY NANO-STRUCTURES AND ARRAYS FOR PHOTOVOLTAICS AND METHODS OF MAKING THE SAME - A photovoltaic device includes an electron accepting material and an electron donating material. One of the electron accepting or donating materials is configured and dimensioned as a first component of a bulk heterojunction with a predetermined array of first structures, each first structure is substantially equivalent in three dimensional shape, has a substantially equivalent cross-sectional dimension, and where each first structure of the array of first structures has a substantially equivalent orientation with respect to adjacent first structures of the predetermined array forming a substantially uniform array. | 06-17-2010 |
20100101308 | METHODS AND SYSTEMS FOR MULTIFORCE HIGH THROUGHPUT SCREENING - Methods and systems for multiforce high throughput screening are disclosed. According to one aspect, the subject matter includes a high throughput screening system that includes a multiforce plate having a plurality of field forming poles where each field forming pole is positioned on the multiforce plate at a location corresponding to a well in a multiwell plate. The system also includes an exciter assembly with excitation poles positioned at locations corresponding to the field forming poles. The excitation poles are utilized for electrically or magnetically coupling to the field forming poles and for delivering at least one of an electric and magnetic field in the vicinity of the field forming poles. The coupled field forming poles apply force via the field(s) to probes located in the wells of the multiforce plate in order to move the probes and test mechanical properties of specimens in the wells. | 04-29-2010 |
20100057490 | METHODS, SYSTEMS, AND COMPUTER PROGRAM PRODUCTS FOR EVALUATING A PATIENT IN A PEDIATRIC INTENSIVE CARE UNIT - Methods, systems, and computer program products for evaluating a patient in a pediatric intensive care unit (PICU) are disclosed. According to one aspect, a method may include collecting physiological data associated with a patient upon admission to a PICU and at least once after admission to the PICU. The physiological data may be associated with a statistical model, and a risk of mortality of the patient may be continually determined. | 03-04-2010 |
20100051480 | NITRIC OXIDE MICROSENSORS VIA FLUOROSILANE-BASED XEROGEL MEMBRANES - The presently disclosed subject matter relates to sensors for measuring an amount of a gaseous species in a sample. The sensors comprise a gas permeable polysiloxane network membrane, comprising both alkyl and fluorinated alkyl groups. In some embodiments, the polysiloxane network can be formed from the co-condensation of a mixture of an alkylalkoxysilane and a fluorosilane. The presently disclosed subject matter also relates to methods of making the sensors, methods of selectively measuring an amount of a gaseous species, such as nitric oxide, in a sample, and to compositions comprising the polysiloxane networks. | 03-04-2010 |
20090299640 | Methods and Compositions Involving Intrinsic Genes - Disclosed are compositions and methods related intrinsic gene sets and methods and compositions related to detecting and classifying cancer. | 12-03-2009 |
20090281250 | METHODS AND MATERIALS FOR FABRICATING MICROFLUIDIC DEVICES - Materials and Methods are provided for fabricating microfluidic devices. The materials include low surface energy fluoropolymer compositions having multiple cure functional groups. The materials can include multiple photocurable and/or thermal-curable functional groups such that laminate devices can be fabricated. The materials also substantially do not swell in the presence of hydrocarbon solvents. | 11-12-2009 |
20090220789 | TAGGANTS AND METHODS AND SYSTEMS FOR FABRICATING SAME - A micro or nanoparticle ( | 09-03-2009 |
20090216079 | Capsule Imaging Devices, Systems and Methods for in Vivo Imaging Applications - Novel capsule imaging devices, systems and methods are provided for in vivo imaging applications, such as for gastrointestinal applications. A swallowable video imaging device, such as a capsule, can be used with a light filter for in vivo illumination of a target tissue that has absorbed a previously administered biological probe. The target tissue can be distinguished in images transmitted from the video imaging device. Quantification of the signal intensity of fluorescence can be used to assess how progressed the target tissue may be. The target tissue can be therapeutically treated to shrink or kill the target tissue. | 08-27-2009 |
20090023038 | LIQUID MATERIALS FOR USE IN ELECTROCHEMICAL CELLS - Disclosed is the use of liquid precursor materials to prepare a processible polymeric electrolyte, which can be used to form a proton exchange membrane for use in an electrochemical cell. Also disclosed is the use of liquid precursor materials to prepare a processible catalyst ink composition, which can be conformally applied to a proton exchange membrane and a electrode material for use in an electrochemical cell. Also disclosed is the use of a photocurable perfluoropolyether (PFPE) material to form a microfluidic electrochemical cell. | 01-22-2009 |
20080293133 | Textiles for use in bioreactors for expansion and maintenance of cells - A bioreactor for three-dimensional culture of liver cells is disclosed. The device is characterized by the use of textile vasculatures. A model and method for optimizing vasculature parameters is also disclosed. Liver acinar structure and physiological parameters are mimicked by sandwiching cells in the space between the two innermost woven textile hollow fibers, and creating radial flow of media from an outer compartment, through the cell mass compartment, and to an inner compartment. The theoretical optimum hydraulic permeability for the two innermost semi-permeable membranes is determined based on physiological hepatic sinusoidal blood flow and pressures. Experimental studies using a flow rate and pressure monitoring systems in conjunction with phase-contrast velocity-encoded MRI confirm theoretical results. Novel woven vascular tubes with optimum hydraulic permeability are disclosed for culturing hepatocytes in the multi-coaxial bioreactor. | 11-27-2008 |
20080234752 | Surgical plate puller devices and methods for use with surgical bone screw/plate systems - A plate puller device can include a head portion and extension rod portion. The device enables the fastener receiving member to be pulled against a bone surface before a head section of the fastener is advanced within the fastener receiving member into a locked position. The head portion can be positioned between the head section of the fastener and a surface of the fastener receiving member not adjacent to the bone surface. Also, a plate puller device can include a screwdriver, a grasper portion and a grasper sleeve. The grasper portion and grasper sleeve can be threadingly mated wherein rotation of the grasper sleeve forces a head portion of the grasper portion to grip the head section of the fastener to prevent the head section from advancing within the fastener receiving member. | 09-25-2008 |
20080233572 | METHODS AND COMPOSITIONS FOR THE DETECTION AND QUANTIFICATION OF E.COLI AND ENTEROCOCCUS - The present invention is drawn to methods and compositions for the rapid assessment of fecal indicator bacteria in a sample. Provided herein are novel primer and probe compositions for use in detecting the presence of these organisms in a sample, particularly using quantitative PCR methods. Provided herein are novel oligonucleotide primers and probes, including the primers set forth in SEQ ID NO:1-4, the novel oligonucleotide probe sequences set forth in SEQ ID NO:5-8, and methods for using these primers and probes for the detection and/or quantification of fecal indicator bacteria, particularly | 09-25-2008 |